Impulse control disorders arising in 3 patients treated with rotigotine.

Published

Journal Article

OBJECTIVE: We report 3 cases of impulse control disorders (ICDs) that developed in patients with Parkinson disease treated with the novel dopamine agonist, rotigotine. METHODS: Three patients were identified retrospectively who developed symptoms of an ICD while taking rotigotine. The ICD symptoms developed at 4, 5, and 8 years after diagnosis of Parkinson disease in these patients and while they were taking rotigotine and levodopa. Other drugs included entacapone, amantadine, and selegiline. The first patient developed symptoms of hypersexuality while taking rotigotine 18 mg (40-cm2 patch) daily and levodopa 300 mg/d. The second patient developed pathological gambling while taking rotigotine 22.5 mg (50-cm2 patch) daily and levodopa 300 mg/d. The third patient developed symptoms of hypersexuality, punding, and pathological gambling, losing more than $100,000 while taking rotigotine 18 mg (40-cm2 patch) and levodopa 400 mg/d. In the first 2 patients, the development of the ICD was temporally associated with an increase in rotigotine dosage, whereas the third patient experienced a dramatic increase in his gambling with the addition of rotigotine. Both subjects who developed pathological gambling had a history of recreational gambling for many years, and 1 of the 2 subjects who developed hypersexuality had a history of cross-dressing since childhood. RESULT: The ICDs in these patients were effectively treated with rotigotine reduction or discontinuation. CONCLUSION: Rotigotine has the potential for causing ICD, similar to other dopamine agonists.

Full Text

Duke Authors

Cited Authors

  • Wingo, TS; Evatt, M; Scott, B; Freeman, A; Stacy, M

Published Date

  • March 2009

Published In

Volume / Issue

  • 32 / 2

Start / End Page

  • 59 - 62

PubMed ID

  • 18978496

Pubmed Central ID

  • 18978496

Electronic International Standard Serial Number (EISSN)

  • 1537-162X

Digital Object Identifier (DOI)

  • 10.1097/WNF.0B013E3181684542

Language

  • eng

Conference Location

  • United States